Home/Filings/4/0000950170-24-003632
4//SEC Filing

Sepp-Lorenzino Laura 4

Accession 0000950170-24-003632

CIK 0001652130other

Filed

Jan 9, 7:00 PM ET

Accepted

Jan 10, 4:15 PM ET

Size

7.1 KB

Accession

0000950170-24-003632

Insider Transaction Report

Form 4
Period: 2024-01-08
Sepp-Lorenzino Laura
EVP, Chief Scientific Officer
Transactions
  • Sale

    Common Stock

    2024-01-08$29.38/sh667$19,59643,927 total
  • Sale

    Common Stock

    2024-01-08$28.66/sh1,608$46,08544,594 total
Footnotes (3)
  • [F1]The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.16 to $29.06, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 8, 2024 at each separate price.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.19 to $29.63, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 8, 2024 at each separate price.

Documents

1 file

Issuer

Intellia Therapeutics, Inc.

CIK 0001652130

Entity typeother

Related Parties

1
  • filerCIK 0001777421

Filing Metadata

Form type
4
Filed
Jan 9, 7:00 PM ET
Accepted
Jan 10, 4:15 PM ET
Size
7.1 KB